These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 7591242

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Relationship of glutathione and glutathione-S-transferase to cisplatin sensitivity in human head and neck squamous carcinoma cell lines.
    Yellin SA, Davidson BJ, Pinto JT, Sacks PG, Qiao C, Schantz SP.
    Cancer Lett; 1994 Oct 14; 85(2):223-32. PubMed ID: 7954341
    [Abstract] [Full Text] [Related]

  • 23. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL, Hwang J, Perng RP, Whang-Peng J.
    Oncol Res; 1995 Oct 14; 7(1):31-8. PubMed ID: 7549042
    [Abstract] [Full Text] [Related]

  • 24. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B.
    Ahmed Z, Deyama Y, Yoshimura Y, Suzuki K.
    Cancer Chemother Pharmacol; 2009 Mar 14; 63(4):643-50. PubMed ID: 18545997
    [Abstract] [Full Text] [Related]

  • 25. Transient increase in squamous cell carcinoma antigen expression in cultured cervical carcinoma CaSki cells in response to exposure to cis-diamminedichloroplatinum.
    Tateiwa Y, Yoshida S, Miyahara Y, Hamana S, Motoyama S, Maruo T.
    Tumour Biol; 2003 Mar 14; 24(5):219-27. PubMed ID: 15001834
    [Abstract] [Full Text] [Related]

  • 26. Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism.
    Maeda S, Sugiura T, Saikawa Y, Kubota T, Otani Y, Kumai K, Kitajima M.
    Cancer Sci; 2004 Aug 14; 95(8):679-84. PubMed ID: 15298732
    [Abstract] [Full Text] [Related]

  • 27. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells.
    Goto S, Yoshida K, Morikawa T, Urata Y, Suzuki K, Kondo T.
    Cancer Res; 1995 Oct 01; 55(19):4297-301. PubMed ID: 7671239
    [Abstract] [Full Text] [Related]

  • 28. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
    Yoshizawa K, Nozaki S, Kitahara H, Ohara T, Kato K, Kawashiri S, Yamamoto E.
    Oncol Rep; 2007 Oct 01; 18(4):987-91. PubMed ID: 17786364
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
    Nishikawa K, Rosenblum MG, Newman RA, Pandita TK, Hittelman WN, Donato NJ.
    Cancer Res; 1992 Sep 01; 52(17):4758-65. PubMed ID: 1380890
    [Abstract] [Full Text] [Related]

  • 34. Intracellular accumulation of thallium as a marker of cisplatin cytotoxicity in nonsmall cell lung carcinoma: an application of inductively coupled plasma mass spectrometry.
    Hanada T, Isobe H, Saito T, Ogura S, Takekawa H, Yamazaki K, Tokuchi Y, Kawakami Y.
    Cancer; 1998 Sep 01; 83(5):930-5. PubMed ID: 9731897
    [Abstract] [Full Text] [Related]

  • 35. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K, Oshima T, Kobayashi T, Yamamoto N, Hayashi C, Matsumoto T, Miwa H.
    Anticancer Res; 2008 Sep 01; 28(4B):2087-92. PubMed ID: 18751380
    [Abstract] [Full Text] [Related]

  • 36. Interactions of interferon-alpha 2a with 5'-deoxy-5-fluorouridine in colorectal cancer cells in vitro.
    Tevaearai HT, Laurent PL, Suardet L, Eliason JF, Givel JC, Odartchenko N.
    Eur J Cancer; 1992 Sep 01; 28(2-3):368-72. PubMed ID: 1534247
    [Abstract] [Full Text] [Related]

  • 37. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.
    Fujishima H, Nakano S, Masumoto N, Esaki T, Tatsumoto T, Kondo T, Niho Y.
    Oncol Res; 1997 Sep 01; 9(4):167-72. PubMed ID: 9268987
    [Abstract] [Full Text] [Related]

  • 38. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N, Lam YM, Pym J, Campling BG.
    Cancer; 1996 May 01; 77(9):1797-808. PubMed ID: 8646677
    [Abstract] [Full Text] [Related]

  • 39. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
    Ohmori T, Morikage T, Sugimoto Y, Fujiwara Y, Kasahara K, Nishio K, Ohta S, Sasaki Y, Takahashi T, Saijo N.
    Jpn J Cancer Res; 1993 Jan 01; 84(1):83-92. PubMed ID: 8383649
    [Abstract] [Full Text] [Related]

  • 40. Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line.
    Koropatnick J, Kloth DM, Kadhim S, Chin JL, Cherian MG.
    J Pharmacol Exp Ther; 1995 Dec 01; 275(3):1681-7. PubMed ID: 8531144
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.